Antioxidant therapy in multiple sclerosis

References

• Ghafourifar, P.; Mousavizadeh, K.; Parihar, MS.; Nazarewicz, RR.; Parihar, A., and Zenebe, WJ. Mitochondria in multiple sclerosis. Front. Biosci. 2008, 13:3116–26.
   PubMed Web of Science ®Google Scholar
• Halliwell, B., and Gutteridge, MC. Oxygen radicals and the nervous system. Trends Neurosci. 1985, 822–29.
   Google Scholar
• van Horssen, J.; Schreibelt, G.; Bö, L.; Montagne, L.; Drukarch, B.; van Muiswinkel, FL., and de Vries, HE. NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions. Free Radic. Biol. Med. 2006, 41:311–317.
   PubMedGoogle Scholar
• Gilgun-Sherki, Y.; Melamed, E., and Offen, D. The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. J. Neurol. 2004, 251:261–268.
   PubMed Web of Science ®Google Scholar
• Schreibelt, G.; van Horssen, J.; van Rossum, S.; Dijkstra, CD.; Drukarch, B., and de Vries, HE. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res. Rev. 2007, 56:322–330.
   PubMedGoogle Scholar
• Trapp, BD.; Peterson, J.; Ransohoff, RM.; Rudick, R.; Mörk, S., and Bö, L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278–85.
   PubMed Web of Science ®Google Scholar
• Mirshafiey, A. Venom therapy in multiple sclerosis. Neuropharmacology. 2007, 53:353–61.
   PubMedGoogle Scholar
• Endres, M. Statins: Potential new indications in inflammatory conditions. Atheroscler Suppl. 2006, 7:31–5.
   PubMed Web of Science ®Google Scholar
• Frohman, EM.; Racke, MK., and Raine, CS. Multiple sclerosis the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942–55.
   PubMed Web of Science ®Google Scholar
• Mirshafiey, A. Novel promising therapeutic agents in multiple sclerosis. Recent patents on inflammation & allergy drug discovery. 2007, 1:218–224.
   PubMedGoogle Scholar
• Noseworthy, JH. Progress in determining the causes and treatment of multiple sclerosis. Nature. 1999, 399:A40–7.
   PubMed Web of Science ®Google Scholar
• Noseworthy, JH.; Lucchinetti, C.; Rodriguez, M., and Weinshenker, BG. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938–52.
   PubMed Web of Science ®Google Scholar
• Schrijver, HM.; Crusius, JB.; Uitdehaag, BM.; García González, MA.; Kostense, PJ.; Polman, CH., and Peña, AS. Association of interleukin- 1 beta and interleukin-1 receptor antagonist genes with diseases severity in MS. Neurology. 1999, 52:595–9.
   PubMedGoogle Scholar
• Myhr, KM.; Raknes, G.; Nyland, H., and Vedeler, C. Immunoglobulin G Fc receptor (Fc gamma R) IIA and IIIB polymorphisms related to disability in MS. Neurology 1999, 52:1771–1776.
   PubMed Web of Science ®Google Scholar
• Evangelou, N.; Jackson, M.; Beeson, D., and Palace, J. Association of the APOE epsilon 4 allele with disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 1999, 67:203–205.
   PubMed Web of Science ®Google Scholar
• Sadovnick, AD.; Armstrong, H.; Rice, GP.; Bulman, D.; Hashimoto, L.; Paty, DW.; Hashimoto, SA.; Warren, S.; Hader, W.; Murray, TJ., and et al A population-based study of multiple sclerosis in twins: Update. Ann. Neurol. 1993, 33:281–285.
   PubMed Web of Science ®Google Scholar
• Jersild, C.; Fog, T.; Hansen, GS.; Thomsen, M.; Svejgaard, A., and Dupont, B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet. 1973, 2:1221–5.
   PubMed Web of Science ®Google Scholar
• Weinshenker, BG.; Santrach, P.; Bissonet, AS.; McDonnell, SK.; Schaid, D.; Moore, SB., and Rodriguez, M. Major histocompatibility complex class II alleles and the course and outcome of MS: a population- based study. Neurology. 1998, 51:742–747.
   PubMedGoogle Scholar
• Gilgun-Sherki, Y.; Melamed, E., and Offen, D. The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. J. Neurol. 2004, 251:261–268.
   PubMed Web of Science ®Google Scholar
• Genain, CP.; Cannella, B.; Hauser, SL., and Raine, CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 1999, 5:170–5.
   PubMed Web of Science ®Google Scholar
• Linington, C.; Berger, T.; Perry, L.; Weerth, S.; Hinze-Selch, D.; Zhang, Y.; Lu, HC.; Lassmann, H., and Wekerle, H. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur. J. Immunol. 1993, 23:1364–72.
   PubMed Web of Science ®Google Scholar
• Xiao, BG., and Link, H. Antigen-specific T cells in autoimmune diseases with a focus on multiple sclerosis and experimental allergic encephalomyelitis. Cell Mol. Life Sci. 1999, 56:5–21.
   PubMed Web of Science ®Google Scholar
• Swanborg, RH. Animal models of human disease: experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin Immunol. Immunopathol. 1995, 77:4–13.
   PubMedGoogle Scholar
• Calabrese, V.; Lodi, R.; Tonon, C.; D’Agata, V.; Sapienza, M.; Scapagnini, G.; Mangiameli, A.; Pennisi, G.; Stella, AM., and Butterfield, DA. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich’s ataxia. J. Neurol. Sci. 2005, 233:145–62.
   PubMed Web of Science ®Google Scholar
• Ruuls, SR.; Bauer, J.; Sontrop, K.; Huitinga, I.; ‘t Hart, BA., and Dijkstra, CD. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J. Neuroimmunol. 1995, 56:207–217.
   PubMed Web of Science ®Google Scholar
• Lambeth, JD. NOX enzymes and the biology of reactive oxygen. Nat Rev. Immunol. 2004, 4:181–189.
   PubMed Web of Science ®Google Scholar
• Segal, BH.; Leto, LT.; Gallin, JI.; Malech, HL., and Holland, SM. Genetic biochemical and clinical features of chronic granulomatous disease. Medicine. 2000, 79:170–200.
   PubMed Web of Science ®Google Scholar
• Ilhan, A.; Akyol, O.; Gurel, A.; Armutcu, F.; Iraz, M., and Oztas, E. Protective effects of caffeic acid phenethyl ester against experimental allergic encephalomyelitis-induced oxidative stress in rats. Free Radic. Biol. Med. 2004, 37:386–394.
   PubMedGoogle Scholar
• Abdala-Valencia, H., and Cook-Mills, JM. VCAM-1 signals activate endothelial cell protein kinase cα via oxidation. J. Immunol. 2006, 177:6379–6387.
   PubMed Web of Science ®Google Scholar
• Tudor, KS.; Hess, KL., and Cook-Mills, JM. Cytokines modulate endothelial cell intracellular signal transduction required for VCAM-1-dependent lymphocyte transendothelial migration. Cytokine. 2001, 15:196–211.
   PubMedGoogle Scholar
• Deem, TL., and Cook-Mills, JM. Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: Role of reactive oxygen species. Blood. 2004, 104:2385–93.
   PubMed Web of Science ®Google Scholar
• Hamedani, M.; Vatanpour, H.; Saadat, F.; Reza Khorramizaheh, M., and Mirshafiey, A. Bee venom, immunostimulant or immunosuppressor? Insight into the effect on matrix metalloproteinases and interferons. Immunopharmacol. Immunotoxicol. 2005, 27:671–81.
   PubMed Web of Science ®Google Scholar
• Matheny, HE.; Deem, TL., and Cook-Mills, JM. Lymphocyte migration through monolayers of endothelial cell lines involves VCAM-1 signaling via endothelial cell NADPH oxidase. J. Immunol. 2000, 164:6550–655.
   PubMed Web of Science ®Google Scholar
• Baron, JL.; Madri, JA.; Ruddle, NH.; Hashim, G., and Janeway, CA Jr. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 1993, 177:57–68.
   PubMed Web of Science ®Google Scholar
• Savina, A.; Jancic, C.; Hugues, S.; Guermonprez, P.; Vargas, P.; Moura, IC.; Lennon-Dumenil, AM.; Seabra, MC.; Raposo, G., and Amigorena, S. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell. 2006, 126:205–218.
   PubMed Web of Science ®Google Scholar
• Park, B.; Lee, S.; Kim, E.; Cho, K.; Riddell, SR.; Cho, S., and Ahn, K. Redox regulation facilitates optimal peptide selection by MHC class I during antigen processing. Cell. 2006, 127:369–382.
   PubMed Web of Science ®Google Scholar
• Lucas, M.; Rodríguez, MC.; Gata, JM.; Zayas, MD.; Solano, F., and Izquierdo, G. Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients. Neurochem. Int. 2003, 42:67–71.
   PubMed Web of Science ®Google Scholar
• LeVine, SM. The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med. Hypotheses. 1992, 39:271–274.
   PubMed Web of Science ®Google Scholar
• Lu, F.; Selak, M.; O’Connor, J.; Croul, S.; Lorenzana, C.; Butunoi, C., and Kalman, B. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic lesions of multiple sclerosis. J. Neurol. Sci. 2000, 177:95–103.
   PubMed Web of Science ®Google Scholar
• Brück, W.; Sommermeier, N.; Bergmann, M.; Zettl, U.; Goebel, HH.; Kretzschmar, HA., and Lassmann, H. Macrophages in multiple sclerosis. Immunobiology. 1996, 195:588–600.
   PubMed Web of Science ®Google Scholar
• Nicholls, D. Mitochondrial bioenergetics, aging, and aging- related disease. Sci. Aging Knowl. Environ. 2002, pe12:
   Google Scholar
• Beckman, KB., and Ames, BN. The free radical theory of aging matures. Physiol. Rev. 1998, 78:547–581.
   PubMed Web of Science ®Google Scholar
• Mirshafiey, A.; Matsuo, H.; Nakane, S.; Rehm, BH.; Koh, CS., and Miyashi, S. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol Immunotoxicol. 2005, 27 (2):255–65.
   PubMedGoogle Scholar
• Vladimirova, O.; Lu, FM.; Shawver, L., and Kalman, B. The activation of protein kinase C induces higher production of reactive oxygen species by mononuclear cells in patients with multiple sclerosis than in controls. Inflamm. Res. 1999, 48:412–6.
   PubMed Web of Science ®Google Scholar
• Vrabec, JP.; Lieven, CJ., and Levin, LA. Cell-type-specific opening of the retinal ganglion cell mitochondrial permeability transition pore. Invest. Ophthalmol. Vis. Sci. 2003, 44:2774–2782.
   PubMedGoogle Scholar
• Banisor, I., and Kalman, B. Bcl-2 and its homologues in the brain of patients with multiple sclerosis. Mult. Scler. 2004, 10:176–181.
   PubMedGoogle Scholar
• Tajouri, L.; Mellick, AS.; Ashton, KJ.; Tannenberg, AE.; Nagra, RM.; Tourtellotte, WW., and Griffiths, LR. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Res. Mol. Brain Res. 2003, 119:170–183.
   PubMedGoogle Scholar
• Radi, R.; Beckman, JS.; Bush, KM., and Freeman, BA. Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys. 1991, 288:481–487.
   PubMed Web of Science ®Google Scholar
• Beckman, JS.; Ye, YZ.; Anderson, PG.; Chen, J.; Accavitti, MA.; Tarpey, MM., and White, CR. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol. Chem. Hoppe-Seyler. 1994, 375:81–88.
   PubMed Web of Science ®Google Scholar
• Ischiropoulos, H.; Zhu, L.; Chen, J.; Tsai, M.; Martin, J.; Smith, C., and Beckman, JS. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 1992, 298 (4):31–437.
   Google Scholar
• Bagasra, O.; Michaels, FH.; Zheng, YM.; Bobroski, LE.; Spitsin, SV.; Fu, ZF.; Tawadros, R., and Koprowski, H. Activation of the inducible form of nitric oxide synthase in the brains of the patients with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:12041–5.
   PubMed Web of Science ®Google Scholar
• Cross, AH.; Manning, PT.; Keeling, RM.; Schmidt, RE., and Misko, TP. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J. Neuroimmunol. 1998, 88:45–56.
   PubMed Web of Science ®Google Scholar
• Calabrese, V.; Scapagnini, G.; Ravagna, A.; Bella, R.; Butterfield, DA.; Calvani, M.; Pennisi, G., and Giuffrida Stella, AM. Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem. Res. 2003, 28:1321–1328.
   PubMedGoogle Scholar
• Cross, AH.; Manning, PT.; Stern, MK., and Misko, TP. Evidence for the production of peroxynitrite in inflammatory CNS demyelination. J. Neuroimmunol. 1997, 80:121–130.
   PubMed Web of Science ®Google Scholar
• Tran, EH.; Hardin-Pouzet, H.; Verge, G., and Owens, T. Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalomyelitis. J. Neuroimmunol. 1997, 74:121–129.
   PubMedGoogle Scholar
• Bates, TE.; Heales, SJ.; Davies, SE.; Boakye, P., and Clark, JB. Effects of 1-Methyl-4-phenylpyridinium on isolated rat brain mitochondria: Evidence for a primary involvement of energy depletion. J. Neurochem. 1994, 63:640–648.
   PubMedGoogle Scholar
• Nathoo, N.; Barnett, GH., and Golubic, M. The eicosanoid cascade: possible role in gliomas and meningiomas. J. Clin.Pathol. 2004, 57:6–13.
   PubMed Web of Science ®Google Scholar
• Farooqui, AA., and Horrocks, LA. Lipid peroxides in the free radical pathophysiology of brain diseases. Cell Mol. Neurobiol. 1998, 18:599–608.
   PubMed Web of Science ®Google Scholar
• Kwak, MK.; Wakabayashi, N.; Itoh, K.; Motohashi, H.; Yamamoto, M., and Kensler, TW. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 2003, 278:8135–45.
   PubMed Web of Science ®Google Scholar
• Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; O’Connor, T., and Yamamoto, M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells. 2003, 8:379–91.
   PubMed Web of Science ®Google Scholar
• McCord, JM., and Edeas, MA. SOD, oxidative stress and human pathologies: A brief history and a future vision. Biomed. Pharmacother. 2005, 59:139–42.
   PubMed Web of Science ®Google Scholar
• Dringen, R.; Pawlowski, PG., and Hirrlinger, J. Peroxide detoxification by brain cells. J. Neurosci. Res. 2005, 79:157–65.
   PubMed Web of Science ®Google Scholar
• Kim, YJ.; Ahn, JY.; Liang, P.; Ip, C.; Zhang, Y., and Park, YM. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res. 2007, 67:546–54.
   PubMed Web of Science ®Google Scholar
• Wagener, FA.; Volk, HD.; Willis, D.; Abraham, NG.; Soares, MP.; Adema, GJ., and Figdor, CG. Different faces of the heme–heme oxygenase system in inflammation. Pharmacol. Rev. 2003, 55:551–71.
   PubMed Web of Science ®Google Scholar
• Thimmulappa, RK.; Mai, KH.; Srisuma, S.; Kensler, TW.; Yamamot, M., and Biswal, S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 2002, 62:5196–203.
   PubMed Web of Science ®Google Scholar
• Jaiswal, AK. Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic. Biol. Med. 2000, 29:254–262.
   PubMed Web of Science ®Google Scholar
• Ahlgren-Beckendorf, JA.; Reising, AM.; Schander, MA.; Herdler, JW., and Johnson, JA. Coordinate regulation of NAD(P.H:quinone oxidoreductase and glutathione-S-transferases in primary cultures of rat neurons and glia: Role of the antioxidant/electrophile responsive element. Glia. 1999, 25:131–142.
   PubMedGoogle Scholar
• Tajouri, L.; Mellick, AS.; Ashton, KJ.; Tannenberg, AE.; Nagra, RM.; Tourtellotte, WW., and Griffiths, LR. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res. Mol. Brain Res. 2003, 119:170–183.
   PubMedGoogle Scholar
• Guy, J.; Qi, X., and Hauswirth, WW. Adeno-associated viral- mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13847–13852.
   PubMed Web of Science ®Google Scholar
• van-Meeteren, ME.; Teunissen, CE.; Dijkstra, CD., and van Tol, EA. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur. J. Clin. Nutr. 2005, 59:1347–1361.
   PubMedGoogle Scholar
• Zachara, BA.; Gromadzinska, J.; Sklodowska, M.; Wasowicz, W.; Czernicki, J., and Maciejek, Z. Selenium status, glutathione peroxidase activity and lipid peroxides concentration in blood of multiple sclerosis patients. Acta Pharmacol. Toxicol. 1986, 59:446–449.
   PubMedGoogle Scholar
• Meister, A. Glutathione-ascorbic acid antioxidant system in animals. J. Biol. Chem. 1994, 269:9397–9400.
   PubMed Web of Science ®Google Scholar
• Marklund, SL.; Westman, NG.; Lundgren, E., and Roos, G. Copper- and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase, and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Res. 1982, 42:1955–1961.
   PubMed Web of Science ®Google Scholar
• Power, JH.; Shannon, JM.; Blumbergs, PC., and Gai, WP. Nonselenium glutathione peroxidase in human brain: elevated levels in Parkinson’s disease and dementia with lewy bodies. Am. J. Pathol. 2002, 161:885–894.
   PubMedGoogle Scholar
• Jensen, GE., and Clausen, J. Glutathione peroxidase and reductase, glucose-6-phosphate dehydrogenase and catalase activities in multiple sclerosis. J. Neurol. Sci. 1984, 63:45–53.
   PubMedGoogle Scholar
• Karg, E.; Klivényi, P.; Németh, I.; Bencsik, K.; Pintér, S., and Vécsei, L. Nonenzymatic antioxidants of blood in multiple sclerosis. J. Neurol. 1999, 246:533–539.
   PubMed Web of Science ®Google Scholar
• Deneke, SM.; Steiger, V., and Fanburg, BL. Effect of hyperoxia on glutathione levels and glutamic acid uptake in endothelial cells. J. Appl. Physiol. 1987, 63:1966–1971.
   PubMed Web of Science ®Google Scholar
• Toshniwal, PK., and Zarling, EJ. Evidence for increased lipid peroxidation in multiple sclerosis. Neurochem. Res. 1992, 17:205–207.
   PubMed Web of Science ®Google Scholar
• Calabrese, V.; Scapagnini, G.; Ravagna, A.; Bella, R.; Foresti, R.; Bates, TE.; Giuffrida Stella, AM., and Pennisi, G. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J. Neurosci Res. 2002, 70:580–587.
   PubMed Web of Science ®Google Scholar
• Thorburne, SK., and Juurlink, BH. Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. J. Neurochem. 1996, 67:1014–1022.
   PubMed Web of Science ®Google Scholar
• Moss, DW., and Bates, TE. Activation of murine microglial cell lines by lipopolysaccharide and interferon- causes NO-mediated decreases in mitochondrial and cellular function. Eur. J. Neurosci. 2001, 13:529–538.
   PubMed Web of Science ®Google Scholar
• Mayer, M., and Noble, M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc. Natl. Acad.Sci. U.S.A. 1994, 91:7496–7500.
   PubMed Web of Science ®Google Scholar
• Bizzozero, OA.; Dejesus, G.; Callahan, K., and Pastuszyn, A. Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J. Neurosci. Res. 2005, 81:687–695.
   PubMed Web of Science ®Google Scholar
• Levine, SM., and Chakrabarty, A. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann. N.Y. Acad. Sci. 2004, 1012:252–266.
   PubMedGoogle Scholar
• Andrews, HE.; Nichols, PP.; Bates, D., and Turnbull, DM. Mitochondrial dysfunction plays a key role in progressive axonal loss in multiple sclerosis. Med. Hypotheses. 2005, 64:669–677.
   PubMed Web of Science ®Google Scholar
• Butterfield, DA., and Lauderback, CM. Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 2002, 32:1050–1060.
   PubMed Web of Science ®Google Scholar
• Bizzozero, OA.; Ziegler, JL.; De Jesus, G., and Bolognani, F. Acute depletion of reduced glutathione causes extensive carbonylation of rat brain proteins. J. Neurosci. Res. 2006, 83:656–667.
   PubMedGoogle Scholar
• Hofmann, B.; Hecht, HJ., and Flohe, L. Peroxiredoxins. Biol. Chem. 2002, 383:347–364.
   PubMed Web of Science ®Google Scholar
• McCord, JM. Iron- and manganese-containing superoxide dismutases: structure, distribution, and evolutionary relationships. Adv. Exp. Med. Biol. 1976, 74:540–550.
   PubMedGoogle Scholar
• Marklund, SL.; Westman, NG.; Lundgren, E., and Roos, G. Copper- and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase, and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Res. 1982, 42:1955–1961.
   PubMed Web of Science ®Google Scholar
• Orr, WC.; Mockett, RJ.; Benes, JJ., and Sohal, RS. Effects of overexpression of copper–zinc and manganese superoxide dismutases, catalase, and thioredoxin reductase genes on longevity in Drosophila melanogaster. J. Biol. Chem. 2003, 278:26418–26422.
   PubMed Web of Science ®Google Scholar
• Afonso, V.; Champy, R.; Mitrovic, D.; Collin, P., and Lomri, A. Reactive oxygen species and superoxide dismutases: Role in joint diseases. Joint Bone Spine. 2007, 74:324–329.
   PubMed Web of Science ®Google Scholar
• Morten, KJ.; Ackrell, BA., and Melov, S. Mitochondrial reactive oxygen species in mice lacking superoxide dismutase 2: Attenuation via antioxidant treatment. J. Biol. Chem. 2006, 281:3354–3359.
   PubMed Web of Science ®Google Scholar
• Kiningham, KK.; Xu, Y.; Daosukho, C.; Popova, B., and St Clair, DK. Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2.. Biochem. J. 2001, 353:147–156.
   PubMed Web of Science ®Google Scholar
• Fattman, CL.; Schaefer, LM., and Oury, TD. Extracellular superoxide dismutase in biology and medicine. Free Radic Biol. Med. 2003, 35:236–256.
   PubMed Web of Science ®Google Scholar
• Enghild, JJ.; Thogersen, IB.; Oury, TD.; Valnickova, Z.; Hojrup, P., and Crapo, JD. The heparin-binding domain of extracellular superoxide dismutase is proteolytically processed intracellularly during biosynthesis. J. Biol. Chem. 1999, 274:14818–14822.
   PubMedGoogle Scholar
• Ceballos, I.; Javoy-Agid, F.; Delacourte, A.; Defossez, A.; Lafon, M.; Hirsch, E.; Nicole, A.; Sinet, PM., and Agid, Y. Neuronal localization of copper–zinc superoxide dismutase protein and mRNA within the human hippocampus from control and Alzheimer’s disease brains. Free Radic. Res. Commun. 1991, 2:571–80.
   Google Scholar
• Zagórski, T.; Dudek, I.; Berkan, L.; Mazurek, M.; Kedziora, J., and Chmielewski, H. [Superoxide dismutase (SOD–1) activity in erythrocytes of patients with multiple sclerosis].. Neurol. Neurochir. Pol. 1991, 25:725–30.
   PubMedGoogle Scholar
• Qi, X.; Guy, J.; Nick, H.; Valentine, J., and Rao, N. Increase of manganese superoxide dismutase, but not of Cu/Zn–SOD, in experimental optic neuritis. Invest. Ophthalmol. Vis. Sci. 1997, 38:1203–1212.
   PubMedGoogle Scholar
• Peng, J.; Stevenson, FF.; Doctrow, SR., and Andersen, JK. Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial nigra: implications for Parkinson disease. J. Biol. Chem. 2005, 280:29194–29198.
   PubMed Web of Science ®Google Scholar
• Sharpe, MA.; Ollosson, R.; Stewart, VC., and Clark, JB. Oxidation of nitric oxide by oxomanganese–salen complexes: A new mechanism for cellular protection by superoxide dismutase/catalase mimetics. Biochem. J. 2002, 366:97–107.
   PubMed Web of Science ®Google Scholar
• Bruce, AJ.; Malfroy, B., and Baudry, M. Beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2312–6.
   PubMed Web of Science ®Google Scholar
• Pong, K.; Doctrow, SR., and Baudry, M. Prevention of 1- methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced nitration of tyrosine hydroxylase and neurotoxicity by EUK-134, a superoxide dismutase and catalase mimetic, in cultured dopaminergic neurons. Brain Res. 2000, 881:182–9.
   PubMed Web of Science ®Google Scholar
• Baker, K.; Marcus, CB.; Huffman, K.; Kruk, H.; Malfroy, B., and Doctrow, SR. Synthetic combined superoxide dismutase/catalase mimics are protective as a delayed treatment in a rat stroke mode: A key role for reactive oxygen species in ischemic brain injury. J. Pharmacol. Exp. Ther. 1998, 284:215–221.
   PubMed Web of Science ®Google Scholar
• Jung, C.; Rong, Y.; Doctrow, S.; Baudry, M.; Malfroy, B., and Xu, Z. Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci. Lett. 2001, 304:157–160.
   PubMed Web of Science ®Google Scholar
• Malfroy, B.; Doctrow, SR.; Orr, PL.; Tocco, G.; Fedoseyeva, EV., and Benichou, G. Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen reactive metabolites. Cell. Immunol. 1997, 177:62–68.
   PubMed Web of Science ®Google Scholar
• Osman, R., and Basch, H. On the mechanism of action of superoxide-dismutase ± a theoretical-study. J. Am. Chem. Soc. 1984, 106:5710–5714.
   Web of Science ®Google Scholar
• Aebi, H. Catalase in vitro. Methods Enzymol. 1984, 105:121–126.
   PubMed Web of Science ®Google Scholar
• Baud, O.; Greene, AE.; Li, J.; Wang, H.; Volpe, JJ., and Rosenberg, PA. Glutathione peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide by mature rat oligodendrocytes. J. Neurosc. 2004, 24:1531–1540.
   PubMed Web of Science ®Google Scholar
• Kim, Y S., and Kim, S U. Oligodendroglial cell death induced by oxygen radicals and its protection by catalase. J. Neurosci Res. 1991, 29:100–106.
   PubMedGoogle Scholar
• Guy, J.; McGorray, S.; Fitzsimmons, J.; Beck, B.; Mancuso, A.; Rao, N A., and Hamed, L. Reversals of blood-brain barrier disruption by catalase: A serial magnetic resonance imaging study of experimental optic neuritis. Invest. Ophthalmol. Vis. Sci. 1994, 35:3456–3465.
   PubMedGoogle Scholar
• Guy, J.; Ellis, EA.; Hope, GM., and Rao, NA. Antioxidant enzyme suppression of demyelination in experimental optic neuritis. Curr. Eye Res. 1989, 8:467–477.
   PubMed Web of Science ®Google Scholar
• Qi, X.; Hauswirth, WW., and Guy, J. Dual gene therapy with extracellular superoxide dismutase and catalase attenuates experimental optic neuritis. Mol Vis. 2007, 13:1–11.
   PubMed Web of Science ®Google Scholar
• Van der Goes, A.; Wouters, D.; Van Der Pol, SM.; Huizinga, R.; Ronken, E.; Adamson, P.; Greenwood, J.; Dijkstra, CD., and De Vries, HE. Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier in vitro. FASEB J. 2001, 15:1852–1854.
   PubMedGoogle Scholar
• Smith, KJ.; Kapoor, R., and Felts, PA. Demyelination: The role of reactive oxygen and nitrogen species. Brain Pathol. 1999, 9:69–92.
   PubMed Web of Science ®Google Scholar
• Siegel, D., and Ross, D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues, Free Radic. Biol. Med. 2000, 29:246–253.
   Google Scholar
• Murphy, TH.; Yu, J.; Ng, R.; Johnson, DA.; Shen, H.; Honey, CR., and Johnson, JA. Preferential expression of antioxidant response element mediated gene expression in astrocytes. J. Neurochem. 2001, 76:1670–1678.
   PubMedGoogle Scholar
• Wierinckx, A.; Brevé, J.; Mercier, D.; Schultzberg, M.; Drukarch, B., and Van Dam, AM. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J. Neuroimmunol. 2005, 166:132–43.
   PubMed Web of Science ®Google Scholar
• Yeldandi, AV.; Yeldandi, V.; Kumar, S.; Murthy, CV.; Wang, XD.; Alvares, K.; Rao, MS., and Reddy, JK. Molecular evolution of the urate oxidase-encoding gene in hominid primates: nonsense mutations. Gene. 1991, 109:281–284.
   PubMed Web of Science ®Google Scholar
• Mousavizadeh, K.; Dehpour, AR.; Minagar, A., and Ghafourifar, P. Uric acid: a novel treatment strategy for multiple sclerosis. Trends Pharmacol. Sci. 2003, 24:563–564.
   PubMed Web of Science ®Google Scholar
• Guerrero, AL.; Martín-Polo, J.; Laherrán, E.; Gutiérrez, F.; Iglesias, F.; Tejero, MA.; Rodríguez-Gallego, M., and Alcázar, C. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur. J. Neurol. 2008, 15:394–397.
   PubMed Web of Science ®Google Scholar
• Kean, RB.; Spitsin, SV.; Mikheeva, T.; Scott, GS., and Hooper, DC. The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J. Immunol. 2000, 165:6511–6518.
   PubMed Web of Science ®Google Scholar
• Hediger, MA. Gateway to a long life?. Nature. 2002, 417:393–395.
   PubMed Web of Science ®Google Scholar
• Rentzos, M.; Nikolaou, C.; Anagnostouli, M.; Rombos, A.; Tsakanikas, K.; Economou, M.; Dimitrakopoulos, A.; Karouli, M., and Vassilopoulos, D. Serum uric acid and multiple sclerosis. Neurol. Sci. 2002, 23:183–188.
   PubMedGoogle Scholar
• Hooper, DC.; Spitsin, S.; Kean, RB.; Champion, JM.; Dickson, GM.; Chaudhry, I., and Koprowski, H. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:675–680.
   PubMed Web of Science ®Google Scholar
• Saadat, F.; Cuzzocrea, S.; Di Paolo, R.; Pezeshki, M.; Khorramizadeh, MR.; Sedaghat, M.; Razavi, A., and Mirshafiey, A. Effect of pyrimethamine in experimental rheumatoid arthritis. Med. Sci. Monit. 2005, 11:293–299.
   Google Scholar
• Saleh, D.; Ernst, P.; Lim, S.; Barnes, PJ., and Giaid, A. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: Effect of inhaled glucocorticoid. FASEB J. 1998, 12:929–937.
   PubMed Web of Science ®Google Scholar
• Szabó, C.; Salzman, AL., and Ischiropoulos, H. Endotoxin triggers the expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in the rat aorta in vivo. FEBS Lett. 1995, 363:235–238.
   PubMed Web of Science ®Google Scholar
• Rachmilewitz, D.; Stamler, JS.; Karmeli, F.; Mullins, ME.; Singel, DJ.; Loscalzo, J.; Xavier, RJ., and Podolsky, DK. Peroxynitrite-induced rat colitis:A new model of colonic inflammation. Gastroenterology. 1993, 105:1681–1688.
   PubMed Web of Science ®Google Scholar
• Oury, TD.; Piantadosi, CA., and Crapo, JD. Cold-induced brain edema in mice. Involvement of extracellular superoxide dismutase and nitric oxide. J. Biol. Chem. 1993, 268:15394–15398.
   PubMedGoogle Scholar
• Smith, MA.; Richey Harris, PL.; Sayre, LM.; Beckman, JS., and Perry, G. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J. Neurosci. 1997, 17:2653–2657.
   PubMed Web of Science ®Google Scholar
• Good, PF.; Hsu, A.; Werner, P.; Perl, DP., and Olanow, CW. Protein nitration in Parkinson’s disease. J. Neuropathol Exp. Neurol. 1998, 57:338–342.
   PubMed Web of Science ®Google Scholar
• Crow, JP.; Sampson, JB.; Zhuang, Y.; Thompson, JA., and Beckman, JS. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J. Neurochem. 1997, 69:1936–1944.
   PubMed Web of Science ®Google Scholar
• Pacher, P., and Szabo, C. Role of the peroxynitrite-poly (ADP-ribose) polymerase pathway in human disease. Am. J. Pathol 2008, 173:2–13.
   PubMed Web of Science ®Google Scholar
• Roggensack, AM.; Zhang, Y., and Davidge, ST. Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension. 1999, 33:83–89.
   PubMed Web of Science ®Google Scholar
• Hensley, K.; Tabatabaie, T.; Stewart, CA.; Pye, Q., and Floyd, RA. Nitric oxide and derived species as toxic agents in stroke, AIDS, dementia, and chronic neurodegenerative disorders. Chem Res. Toxicol. 1997, 10:527–532.
   PubMed Web of Science ®Google Scholar
• Toncev, G.; Milicic, B.; Toncev, S., and Samardzic, G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J. Neurol. 2002, 9:221–226.
   PubMed Web of Science ®Google Scholar
• Spitsin, SV.; Scott, GS.; Kean, RB.; Mikheeva, T., and Hooper, DC. Protection of myelin basic protein immunized mice from free-radical mediated inflammatory cell invasion of the central nervous system by the natural peroxynitrite scavenger uric acid. Neurosci Lett. 2000, 292:137–141.
   PubMed Web of Science ®Google Scholar
• Hooper, DC.; Spitsin, S.; Kean, RB.; Champion, JM.; Dickson, GM.; Chaudhry, I., and Koprowski, H. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci. USA. 1998, 95:675–680.
   PubMed Web of Science ®Google Scholar
• Kanabrocki, EL.; Third, JL.; Ryan, MD.; Nemchausky, BA.; Shirazi, P.; Scheving, LE.; McCormick, JB.; Hermida, RC.; Bremner, WF.; Hoppensteadt, DA.; Fareed, J., and Olwin, JH. Circadian relationship of serum uric acid and nitric oxide. J. Am. Med. Assoc. 2000, 283:2240–2241.
   PubMedGoogle Scholar
• Marracci, GH.; McKeon, GP.; Marquardt, WE.; Winter, RW.; Riscoe, MK., and Bourdette, DN. αlipoic acid inhibits human T-cell migration: Implications for multiple sclerosis. J. Neurosci. Res. 2004, 78:362–370.
   PubMed Web of Science ®Google Scholar
• Schreibelt, G.; Musters, RJ.; Reijerkerk, A.; de Groot, LR.; van der Pol, SM.; Hendrikx, EM.; Döpp, ED.; Dijkstra, CD.; Drukarch, B., and de Vries, HE. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. J. Immunol. 2006, 177:2630–2637.
   PubMed Web of Science ®Google Scholar
• Cho, KJ.; Moini, H.; Shon, HK.; Chung, AS., and Packer, L. [alpha]-Lipoic acid decreases thiol reactivity of the insulin receptor and protein tyrosine phosphatase 1B in 3T3–L1 adipocytes. Biochem. Pharmacol. 2003, 66:849–58.
   PubMedGoogle Scholar
• Hooper, DC.; Bagasra, O.; Marini, JC.; Zborek, A.; Ohnish,i, ST.; Kean, R.; Champion, JM.; Sarker, AB.; Bobroski, L.; Farber, JL.; Akaike, T.; Maeda, H., and Koprowski, H. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: Implications for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:2528–2533.
   PubMed Web of Science ®Google Scholar
• Schillace, RV.; Pisenti, N.; Pattamanuch, N.; Galligan, S.; Marracci, GH.; Bourdette, DN., and Carr, DW. Lipoic acid stimulates cAMP production in T lymphocytes and NK cells. Biochem. Biophys Res. Commun. 2007, 354:259–264.
   PubMedGoogle Scholar
• Yadav, V.; Marracc, G.; Lovera, J.; Woodward, W.; Bogardus, K.; Marquardt, W.; Shinto, L.; Morris, C., and Bourdette, D. Lipoic acid in multiple sclerosis: A pilot study. Mult. Scler. 2005, 11:159–165.
   PubMed Web of Science ®Google Scholar
• Frei, B., and Higdon, JV. Antioxidant activity of tea polyphenols in vivo: Evidence from animal studies. J. Nutr. 2003, 133:3275–3284.
   PubMed Web of Science ®Google Scholar
• Bowie, A., and O’Neill, LA. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem. Pharmacol. 2000, 59:13–23.
   PubMed Web of Science ®Google Scholar
• Marracci, GH.; Marquardt, WE.; Strehlow, A.; McKeon, GP.; Gross, J.; Buck, DC.; Kozell, LB., and Bourdette, DN. Lipoic acid downmodulates CD4 from human T lymphocytes by dissociation of p56Lck. Biochem. Biophys. Res. Commun. 2006, 344:963–971.
   PubMed Web of Science ®Google Scholar
• Liu, Y.; Zhu, B.; Wang, X.; Luo, L.; Li, P.; Paty, DW., and Cynader, MS. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: Implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. 2003, 139:27–35.
   PubMed Web of Science ®Google Scholar
• Stocker, R.; Yamamoto, Y.; McDonagh, AF.; Glazer, AN., and Ames, BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987, 235:1043–1046.
   PubMed Web of Science ®Google Scholar
• Liu, Y.; Liu, J.; Tetzlaff, W.; Paty, DW., and Cynader, MS. Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis. Free Radic. Biol. Med. 2006, 40:960–967.
   PubMedGoogle Scholar
• van Meeteren, M.E.; Teunissen, C.E.; Dijkstra, C.D., and van Tol, E.A.F. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur. J. Clin. Nutr. 2005, 59:1347–1361.
   PubMed Web of Science ®Google Scholar
• Simopoulos, AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21:495–505.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman, B.; Baier, M.; Park, Y.; Feichter, J.; Lee-Kwen, P.; Gallagher, E.; Venkatraman, J.; Meksawan, K.; Deinehert, S.; Pendergast, D.; Awad, AB.; Ramanathan, M.; Munschauer, F., and Rudick, R. Low fat dietary intervention with ω-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot. Essent. Fatty Acids. 2005, 73:397–404.
   PubMed Web of Science ®Google Scholar
• Holian, O., and Nelson, R. Action of long-chain fatty acids on protein kinase C activity: Comparison of omega-6 and omega-3 fatty acids. Anticancer Res. 1992, 12:975–980.
   PubMed Web of Science ®Google Scholar
• Calder, PC. Fat chance of immunomodulation. Trends Immunol. Today. 1998, 6:244–247.
   Google Scholar
• Mazza, M.; Pomponi, M.; Janiri, L.; Bria, P., and Mazza, S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases, An overview. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007, 31:12–26.
   PubMed Web of Science ®Google Scholar
• Aupperle, RL.; Denney, DR.; Lynch, SG.; Carlson, SE., and Sullivan, DK. Omega-3 fatty acids and multiple sclerosis: Relationship to depression. J. Behav. Med. 2008, 31:127–135.
   PubMedGoogle Scholar
• Lukiw, WJ.; Cui, JG.; Marcheselli, VL.; Bodke, r M.; Botkjaer, A.; Gotlinger, K.; Serhan, CN., and Bazan, NG. Role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 2005, 115:2774–2783.
   PubMed Web of Science ®Google Scholar
• Rossary, A.; Arab, K., and Steghens, JP. Polyunsaturated fatty acids modulate NOX 4 anion superoxide production in human fibroblasts. Biochem. J. 2007, 406:77–83.
   PubMedGoogle Scholar
• Weinstock-Guttman, B.; Baier, M.; Park, Y.; Feichter, J.; Lee-Kwen, P.; Gallagher, E.; Venkatraman, J.; Meksawan, K.; Deinehert, S.; Pendergast, D.; Awad, AB.; Ramanathan, M.; Munschauer, F., and Rudick, R. Low fat dietary intervention with ω-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot. Essen. Fatty Acids. 2005, 73:397–404.
   PubMed Web of Science ®Google Scholar
• Stepien, K.; Tomaszewski, M., and Czuczwar, SJ. Neuroprotective properties of statins. Pharmacol. Rep. 2005, 57:561–9.
   PubMed Web of Science ®Google Scholar
• Youssef, S.; Stüve, O.; Patarroyo, JC.; Ruiz, PJ.; Radosevich, JL.; Hur, EM.; Bravo, M.; Mitchell, DJ.; Sobel, RA.; Steinman, L., and Zamvil, SS. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002, 420:78–84.
   PubMed Web of Science ®Google Scholar
• Aktas, O.; Waiczies, S.; Smorodchenko, A.; Dorr, J.; Seeger, B.; Prozorovski, T.; Sallach, S.; Endres, M.; Brocke, S.; Nitsch, R., and Zipp, F. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 2003, 197:725–733.
   PubMed Web of Science ®Google Scholar
• Pannu, R., and Singh, I. Pharmacological strategies for the regulation of inducible nitric oxide synthase: Neurodegenerative versus neuroprotective mechanisms. Neurochem. Int. 2006, 49:170–182.
   PubMedGoogle Scholar
• Endres, M. Statins: Potential new indications in inflammatory conditions. Atheroscler Suppl. 2006, 7:31–35.
   PubMed Web of Science ®Google Scholar
• Menge, T.; Hartung, HP., and Stüve, O. Statins—A cure-all for the brain?. Nat. Rev. 2005, 6:325–351.
   Google Scholar
• Galea, E.; Reis, DJ.; Xu, H., and Feinstein, DL. Transient expression of calcium-independent nitric oxide synthase in blood vessels during brain development. FASEB J. 1995, 9:1632–1637.
   PubMedGoogle Scholar
• Pahan, K.; Namboodiri, AM.; Sheikh, FG.; Smith, BT., and Singh, I. Increasing cAMP attenuates induction of inducible nitric-oxide synthase in rat primary astrocytes. J. Biol. Chem. 1997, 272:7786–7791.
   PubMed Web of Science ®Google Scholar
• Besler, HT.; Comoglu, S., and Okçu, Z. Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutr. Neurosci. 2002, 5:215–20.
   PubMed Web of Science ®Google Scholar
• Jiménez-Jiménez, FJ.; de Bustos, F.; Molina, JA.; de Andrés, C.; Gasalla, T.; Ortí-Pareja, M.; Zurdo, M.; Porta, J.; Castellano-Millán, F.; Arenas, J., and Enríquez de Salamanca, R. Cerebrospinal fluid levels of alpha-tocopherol in patients with multiple sclerosis. Neurosci. Lett. 1998, 249:65–67.
   PubMed Web of Science ®Google Scholar
• Jiménez-Jiménez, FJ.; de Bustos, F.; Molina, JA.; Benito-León, J.; Tallón-Barranco, A.; Gasalla, T.; Ortí-Pareja, M.; Guillamón, F.; Rubio, JC.; Arenas, J., and Enríquez-de-Salamanca, R. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer’s disease. J. Neural. Transm. 1997, 104:703–710.
   PubMed Web of Science ®Google Scholar
• Guthikonda, P.; Baker, J., and Mattson, DH. Interferon-beta-1-b (IFN-B) decreases induced nitric oxide (NO) production by a human astrocytoma cell line. J. Neuroimmunol. 1998, 82:133–139.
   PubMedGoogle Scholar
• Thurnham, DI.; Davies, JA.; Crump, BJ.; Situnayake, RD., and Davis, M. The use of different lipids to express serum tocopherol:lipid ratios for the measurement of vitamin E status. Ann. Clin. Biochem. 1986, 23:514–520.
   PubMed Web of Science ®Google Scholar
• Butterfield, DA.; Castegna, A.; Drake, J.; Scapagnini, G., and Calabrese, V. Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr. Neurosci. 2002, 5:229–239.
   PubMed Web of Science ®Google Scholar
• de Andrés, C., and Lledó, A. Fatty diet and multiple sclerosis. Rev. Neurol. 1997, 25:2032–2035.
   PubMedGoogle Scholar
• Chun, TY.; Carman, JA., and Hayes, CE. Retinoid repletion of vitamin A-deficient mice restores IgG responses. J. Nutr. 1992, 122:1062–1069.
   PubMed Web of Science ®Google Scholar
• Qu, ZX.; Dayal, A.; Jensen, MA., and Arnason, BG. All-trans retinoic acid potentiates the ability of interferon beta-1b to augment suppressor cell function in multiple sclerosis. Arch. Neurol. 1998, 55:315–321.
   PubMedGoogle Scholar
• Desvergne, B., and Wahli, W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr. Rev. 1999, 20:649–688.
   PubMed Web of Science ®Google Scholar
• Lee, C-H.; Olson, P., and Evans, RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 2003, 144:2201–2207.
   PubMed Web of Science ®Google Scholar
• Xu, J.; Storer, PD.; Chavis, JA.; Racke, MK., and Drew, PD. Agonists for the peroxisome proliferator-activated receptor-α and the retinoid X receptor inhibit inflammatory responses of microglia. J. Neurosci. Res. 2005, 81:403–411.
   PubMed Web of Science ®Google Scholar
• Pedersen, LB.; Nashold, FE.; Spach, KM., and Hayes, CE. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J. Neurosci. Res. 2007, 85:2480–2490.
   PubMed Web of Science ®Google Scholar
• Spach, KM., and Hayes, CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J. Immunol. 2005, 175:4119–4126.
   PubMed Web of Science ®Google Scholar
• Hayes, CE.; Nashold, FE.; Spach, KM., and Pedersen, LB. The immunological functions of the vitamin D endocrine system. Cell Mol. Biol. (Noisy-le-grand). 2003, 49:277–300.
   PubMed Web of Science ®Google Scholar
• Lambert, JD.; Sang, S., and Yang, CS. Biotransformation of green tea polyphenols and the biological activities of those metabolites. Mol Pharm. 2007, 4:819–25.
   PubMed Web of Science ®Google Scholar
• Révész, K.; Tüttô, A., and Konta, L. Effect of green tea flavonols on the function of the endoplasmic reticulum. Orv Hetil. 2007, 148:1903–7.
   PubMedGoogle Scholar
• Aktas, O.; Prozorovski, T.; Smorodchenko, A.; Savaskan, NE.; Lauster, R.; Kloetzel, PM.; Infante-Duarte, C.; Brocke, S., and Zipp, F. Green Tea Epigallocatechin-3-Gallate mediates t cellular nf-b inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 2004, 173:5794–5800.
   PubMed Web of Science ®Google Scholar
• Haqqi, TM.; Anthony, DD.; Gupta, S.; Ahmad, N.; Lee, MS.; Kumar, GK., and Mukhtar, H. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4524–9.
   PubMed Web of Science ®Google Scholar
• Hinz, M.; Krappmann, D.; Eichten, A.; Heder, A.; Scheidereit, C., and Strauss, M. NF-B function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell Biol. 1999, 19:2690–8.
   PubMed Web of Science ®Google Scholar
• Jiang, RW.; Lau, KM.; Hon, PM.; Mak, TC.; Woo, KS., and Fung, KP. Chemistry and biological activities of caffeic acid derivatives from Salvia miltiorrhiza. Curr. Med. Chem. 2005, 12:237–46.
   PubMed Web of Science ®Google Scholar
• Yang, JQ.; Zho,u, QX.; Liu, BZ., and He, BC. Protection of mouse brain from aluminum-induced damage by caffeic acid. CNS Neurosci. Ther. 2008, 14:10–6.
   PubMed Web of Science ®Google Scholar
• Sud’ina, GF.; Mirzoeva, OK.; Pushkareva, MA.; Korshunova, GA.; Sumbatyan, NV., and Varfolomeev, SD. Caffeic acid phenethyl ester as a lipooxygenase inhibitor with antioxidant properties. FEBS Lett. 1993, 329:21–24.
   PubMed Web of Science ®Google Scholar
• Ilhan, A.; Akyol, O.; lA, Gure.; Armutcu, F.; Iraz, M., and Oztas, E. Protective effects of caffeic acid phenethyl ester against experimental allergic encephalomyelitis-induced oxidative stress in rats. Free Radic. Biol. Med. 2004, 37:386–394.
   PubMedGoogle Scholar
• Song, YS.; Park, EH.; Hur, GM.; Ryu, YS.; Lee, YS.; Lee, JY.; Kim, YM., and Jin, C. Caffeic acid phenethyl ester inhibits nitric oxide synthase gene expression and enzyme activity. Cancer Lett. 2002, 175:53–61.
   PubMed Web of Science ®Google Scholar
• Natarajan, K.; Singh, S.; Burke, TR.Jr.;; Grunberger, D., and Aggarwal, BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NFkappa B.. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9090–9095.
   PubMed Web of Science ®Google Scholar